Emily Rychak

1.9k total citations · 2 hit papers
10 papers, 1.1k citations indexed

About

Emily Rychak is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Emily Rychak has authored 10 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Hematology and 1 paper in Oncology. Recurrent topics in Emily Rychak's work include Protein Degradation and Inhibitors (9 papers), Multiple Myeloma Research and Treatments (9 papers) and Ubiquitin and proteasome pathways (6 papers). Emily Rychak is often cited by papers focused on Protein Degradation and Inhibitors (9 papers), Multiple Myeloma Research and Treatments (9 papers) and Ubiquitin and proteasome pathways (6 papers). Emily Rychak collaborates with scholars based in Japan, Switzerland and United States. Emily Rychak's co-authors include Antonia Lopez‐Girona, Brian E. Cathers, Gilles Carmel, Hiroshi Handa, Takumi Ito, Derek Mendy, Anita K. Gandhi, Rajesh Chopra, Peter Schäfer and Svetlana Gaidarova and has published in prestigious journals such as Blood, Nature Structural & Molecular Biology and British Journal of Haematology.

In The Last Decade

Emily Rychak

10 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

2012 606 citations Antonia Lopez‐Girona, Derek Mendy et al. Leukemia profile →
Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs

2014 371 citations Philip P. Chamberlain, Antonia Lopez‐Girona et al. Nature Structural & Molecular Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emily Rychak Japan	6	969	669	381	87	85	10	1.1k
Huahang Sun United States	2	1.0k 1.0×	523 0.8×	335 0.9×	64 0.7×	104 1.2×	2	1.1k
Mahan Abbasian United States	9	637 0.7×	431 0.6×	281 0.7×	78 0.9×	132 1.6×	13	830
K. Martin Kortuem United States	10	667 0.7×	557 0.8×	276 0.7×	53 0.6×	65 0.8×	20	853
Derek Mendy United States	10	1.1k 1.2×	771 1.2×	518 1.4×	131 1.5×	129 1.5×	21	1.3k
Yan Ren China	12	841 0.9×	588 0.9×	338 0.9×	56 0.6×	114 1.3×	30	1.0k
Bangzheng Chen United States	6	584 0.6×	430 0.6×	320 0.8×	114 1.3×	155 1.8×	8	900
Patrick R. Hagner United States	16	671 0.7×	253 0.4×	271 0.7×	166 1.9×	131 1.5×	51	905
John S. Strader United States	4	582 0.6×	384 0.6×	275 0.7×	40 0.5×	53 0.6×	7	706
Teresa Paíno Spain	14	443 0.5×	333 0.5×	227 0.6×	96 1.1×	63 0.7×	31	629
N. Roubi France	6	558 0.6×	377 0.6×	232 0.6×	33 0.4×	108 1.3×	8	809

Countries citing papers authored by Emily Rychak

Since Specialization

Citations

This map shows the geographic impact of Emily Rychak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Rychak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Rychak more than expected).

Fields of papers citing papers by Emily Rychak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Rychak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Rychak. The network helps show where Emily Rychak may publish in the future.

Co-authorship network of co-authors of Emily Rychak

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Rychak. A scholar is included among the top collaborators of Emily Rychak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Rychak. Emily Rychak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Lopez‐Girona, Antonia, Gang Lu, Emily Rychak, et al.. (2019). CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets GSPT1 for Degradation to Induce Potent Tumoricidal Activity Against Acute Myeloid Leukemia (AML). Blood. 134(Supplement_1). 2703–2703. 16 indexed citations

Lopez‐Girona, Antonia, Courtney G. Havens, Gang Lu, et al.. (2019). CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells. Blood. 134(Supplement_1). 1812–1812. 18 indexed citations

Rychak, Emily, Derek Mendy, Tao Shi, et al.. (2016). Pomalidomide in combination with dexamethasone results in synergistic anti‐tumour responses in pre‐clinical models of lenalidomide‐resistant multiple myeloma. British Journal of Haematology. 172(6). 889–901. 40 indexed citations

Chamberlain, Philip P., Antonia Lopez‐Girona, Karen Miller, et al.. (2014). Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nature Structural & Molecular Biology. 21(9). 803–809. 371 indexed citations breakdown →

Gandhi, Anita K., Derek Mendy, Michelle F. Waldman, et al.. (2013). Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. British Journal of Haematology. 164(2). 233–244. 71 indexed citations

Rychak, Emily, Derek Mendy, Karen Miller, et al.. (2013). The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In Vitro Models Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide. Blood. 122(21). 3160–3160. 1 indexed citations

Lopez‐Girona, Antonia, Derek Mendy, Takumi Ito, et al.. (2012). Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 26(11). 2326–2335. 606 indexed citations breakdown →

Gandhi, Anita K., Hervé Avet‐Loiseau, Michelle F. Waldman, et al.. (2012). Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138+multiple Myeloma Cells. Blood. 120(21). 4043–4043. 1 indexed citations

Schäfer, Peter, Emily Rychak, Derek Mendy, et al.. (2012). Targeting Cereblon with the High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent for B Cell Dyscrasias. Blood. 120(21). 1055–1055. 1 indexed citations

10.

Lopez‐Girona, Antonia, Derek Mendy, Karen Miller, et al.. (2011). Direct Binding with Cereblon Mediates the Antiproliferative and Immunomodulatory Action of Lenalidomide and Pomalidomide. Blood. 118(21). 738–738. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact